Xenter unveils dual-sensor TAVI guidewire


Xenter unveiled its dual sensor investigational guidewire for transcatheter aortic valve implantation (TAVI) procedures at the 2023 TCT conference (23–26 October, San Francisco, USA).

The wireless TAVI guidewire is designed to collect an extensive range of crucial real-time data points to serve as an aortic regurgitation measurement (xAR) and clinical decision support tool, which the company says significantly enhances the prediction of paravalvular leak (PVL) during the procedure.

The guidewire’s functionality is designed to allow for comprehensive data collection and analysis and facilitates data necessary for novel Artificial Intelligence (AI) decision making tools. The goal is to enable better-informed clinical decisions and improve patient outcomes. The guidewire is designed to operate seamlessly within a proprietary wireless ecosystem in the cardiac cath lab making real-time data and analysis more accessible than ever, the company said in a press release.

Rich Linder, chairman/CEO of Xenter, said: “We built Xenter to enable Artificial Intelligence (AI) tools to be utilised with ease and accuracy using new smart/wireless medical devices that transmit real-time PI data. Xenter is pioneering “smart” medical devices and a wireless ecosystem that eliminate the capital equipment and mobile carts that clutter hospitals throughout the world.”

“An excellent example of real-time PI data collection is the TAVI SmartWire”, stated William A Gray (Mainline Healthcare, Philadelphia, USA. “TAVR SmartWire will enable the real-time measurement of aortic and left ventricular pressure information in a single workhorse device that can be used to develop a measurement of aortic regurgitation. We plan to clinically evaluate TAVR SmartWire and provide physicians with a real-time AR measurement called xAR.”

Martin B Leon (Columbia University/New York Presbyterian Hospital, New York, USA), global study chair for TAVR SmartWire, stated: “From the beginning, we saw the need to innovate and engineer new solutions in cardiovascular medicine that can transform how information is collected during interventional procedures, including TAVI. I am looking forward to seeing these innovative solutions make their way into clinical research and to demonstrate the clinical utility of xAR in transcatheter aortic valve replacement.”


Please enter your comment!
Please enter your name here